OCGN
Ocugen, Inc.
There isn't enough reported data to score OCGN yet.
UNH
UnitedHealth Group Incorporated
UNH's fundamentals are mixed: free cash flow grew 31%, but earnings per share fell 8.5%. At 23x earnings, it's trading right at its usual valuation. Analysts expect strong earnings growth, though they disagree widely on how much.
OCGN Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Weak | |
| Unavailable |
OCGN's revenue is currently stable, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
OCGN PE Valuation
OCGN has no meaningful PE right now: it lost money over the past year.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
OCGN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect OCGN's losses to grow, with revenue growing. However, they disagree widely on these estimates.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
OCGN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.20 | +$0.01 |
| Q2 2026 | -$0.26 | -$0.07 |
| Q1 2026 | -$0.24 | -$0.06 |
| Q4 2025 | -$0.23 | -$0.05 |
| Q3 2025 | -$0.21 | -$0.04 |
| Q2 2025 | -$0.19 | -$0.01 |
| Q1 2025 | -$0.18 | +$0.06 |
| Q4 2024 | -$0.18 | +$0.08 |
OCGN is still losing money, but less than at its worst: $0.20 per share over the past year, against $0.38 at its worst in late 2022.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH has the edge over OCGN on earnings quality, reporting a profit while its opponent remains loss making.
OCGN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $2M | +11% |
| Q2 2026 | $1.5M | +8.4% |
| Q1 2026 | $1.5M | +3.5% |
| Q3 2025 | $1.8M | +54% |
| Q2 2025 | $1.4M | +20% |
| Q1 2025 | $1.5M | +46% |
| Q4 2024 | $764K | -46% |
OCGN's revenue is down over the past year, though its latest quarter was up: $2M last quarter, up 11% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -910% | +96 points |
| Q2 2026 | -1105% | -100 points |
| Q1 2026 | -1164% | -185 points |
| Q3 2025 | -1006% | +161 points |
| Q2 2025 | -1005% | +349 points |
| Q1 2025 | -979% | +226 points |
| Q4 2024 | -1812% | -994 points |
| Q3 2024 | -1167% | N/A |
OCGN's operating margin was −910% last quarter, up 95 points from the same quarter a year ago.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH's revenue has held roughly level: $113B last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH has the edge over OCGN on profitability, with a higher operating margin.
OCGN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$15.9M | -$2.9M |
| Q2 2026 | -$12.2M | -$1.4M |
| Q1 2026 | -$21.8M | -$2.4M |
| Q4 2025 | -$14M | -$3.6M |
| Q3 2025 | -$13M | -$1.2M |
| Q2 2025 | -$10.8M | -$349K |
| Q1 2025 | -$19.4M | -$6.4M |
| Q4 2024 | -$10.4M | +$3.6M |
OCGN has burned cash in almost every quarter: −$64M over the past year, against −$54M the year before.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH has the edge over OCGN on cash generation, producing positive trailing cash flow while its opponent burns cash.
OCGN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +534K shares |
| 1 year | +8.6% | +26.9M shares |
| 3 years | +32% | +82.7M shares |
| 5 years | +71% | +140M shares |
| Available history | +545% | +287M shares |
OCGN has 339M diluted shares, up 8.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2025 | — |
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has the edge over OCGN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
OCGN Net Leverage
OCGN's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
OCGN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 39.7 | Neutral |
| Stochastic | 17.9 | Oversold |
OCGN's weekly RSI is 40 (neutral) and its Stochastic is 18 (oversold).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
OCGN PE vs Healthcare Sector
OCGN has no meaningful PE right now: it lost money over the past year.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
OCGN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.88 | 1.1% below |
| 20 week MA | $1.13 | 23% below |
| 50 week MA | $1.39 | 37% below |
| 100 week MA | $1.19 | 27% below |
| 200 week MA | $1.05 | 17% below |
OCGN is in a downtrend: it's below all five of its weekly moving averages, and 17% below its 200-week average.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has the edge over OCGN on trend strength, trading above more of its moving averages.
OCGN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $0.40 | $1.76 | +340% |
| 2021 | $1.76 | $5.30 | +201% |
| 2022 | $5.30 | $1.21 | -77% |
| 2023 | $1.21 | $0.57 | -53% |
| 2024 | $0.57 | $0.85 | +49% |
| 2025 | $0.85 | $1.41 | +66% |
| 2026 YTD | $1.41 | $0.87 | -38% |
OCGN's yearly returns have swung widely, from +340% in 2020 to −77% in 2022. It's down 38% so far in 2026.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has the edge over OCGN on returns for 2026, with the stronger performance.